Beyond Tacrolimus: Towards Personalized Immunosuppression in Heart Transplantation
Realizing the potential of personalized immunosuppression in heart transplantation will require not only a broader suite of validated biomarkers and integrative risk scores, but also novel pragmatic trial designs and surrogate endpoints to support the development of next-generation therapeutics.